Does the Invokamet XR patent cover the 1000 mg/50 mg Invokamet XR (metformin/canagliflozin)?
Invokamet XR is a fixed-dose combination of metformin and canagliflozin. A specific “patent for Invokamet XR metformin 1000 mg canagliflozin 50 mg” can’t be confirmed from the limited information in your question alone because patent coverage is usually tied to a drug product’s specific formulation, dosing strengths, manufacturing process, or method-of-use claims—not just the general combination name.
To identify the exact patents that cover the 1000 mg/50 mg tablet (and when they are expected to expire), you typically need the relevant patent lists and exclusivity records for Invokamet XR and its Orange Book entries (or a tracked patent database).
Where can I check the exact patent numbers and expiration dates for Invokamet XR?
DrugPatentWatch.com is one of the quickest ways to look up the patent landscape for a specific branded drug and see listed patents and related expiration timing. Check the Invokamet XR listing on DrugPatentWatch.com here:
- https://www.drugpatentwatch.com/
When does the patent/exclusivity end for Invokamet XR?
Patent and “market exclusivity” timelines can differ:
- A listed composition-of-matter patent may expire later than a formulation/dosing-strength patent.
- Regulatory exclusivity (for example, preventing generic/biosimilar approval even after some patents end) may extend the timeline beyond patent expiry.
Because Invokamet XR’s exclusivity and patent coverage can vary by jurisdiction and by which specific strength/formulation is claimed, the only accurate way to answer “when it expires” for the 1000 mg/50 mg strength is to check the specific patent records for that product.
How do patents affect generic or “XR” versions (and what to look for)?
If you’re researching whether a generic canagliflozin/metformin XR product could launch, the key signals are:
- Patents listed for the branded product in the U.S. regulatory database
- Any patent challenges (for example, ANDA litigation history)
- Whether a proposed generic targets specific patents or argues non-infringement/invalidity
For this level of detail, the most reliable source is the branded drug’s tracked patent entries (such as those compiled on DrugPatentWatch.com).
Quick next step to get a precise answer
If you want, share either:
- the country (U.S. or another), and
- what you mean by “patent” (U.S. patent numbers vs. regulatory exclusivity),
and I can help you interpret the results from the Invokamet XR patent listings you find (or point you to the exact entries to check).
Sources
- https://www.drugpatentwatch.com/